Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 28;7:231. doi: 10.1186/s40425-019-0676-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 3 — POG, as a natural inhibitor of PMN-MDSCs, is screened by molecular docking and weight calculation of docking scores. a Cytoscape analysis of the proteins in the upregulated KEGG pathway of B16-F10 tumour-bearing PMN-MDSCs and the top 10 key proteins of upregulation proteins of B16-F10 tumour-bearing PMN-MDSCs obtained according to the Cytoscape analysis degree. b Screening result of PMN-MDSC inhibitors from the traditional Chinese Medicine library with the top 10 key proteins as targets by molecular docking and weight calculation of docking score. c The 10 compounds from the traditional Chinese Medicine library, which binds well with 10 key proteins, and the absolute value of docking scores are more than 4 with all 10 proteins. d Weight calculation of the 10 compounds from the traditional Chinese Medicine library. e Inhibitory effect of the top 5 compounds on PMN-MDSCs (CD11b⁺ Ly6G⁺ Ly6C^low) in vitro. f The tumour growth curves of B16-F10 tumour-bearing mice after the top 5 compound treatments (n = 6). g Body weight of B16-F10 tumour-bearing mice after the top 5 compound treatments (n = 6). h Relative proportion of PMN-MDSCs (CD11b⁺ Ly6G⁺ Ly6C^low) in bone marrow, spleen and CD45⁺ cells from tumours of control and top 5 compound-treated B16-F10 tumour-bearing mice (n = 6). i Relative proportion of CD8 T-lymphocytes (CD3⁺CD8⁺) in spleens and CD45⁺ cells from tumours of control and top 5 compound-treated B16-F10 tumour-bearing mice (n = 6). The pooled data from three independent experiments are shown. All data are represented as the mean ± SD. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001